Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report

Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report From June 2015 to June 2016

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02955862

Enrollment

1177

Registered

2016-11-04

Start date

2015-06-30

Completion date

2017-09-30

Last updated

2018-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cryptococcal Meningitis

Keywords

Cryptococcal antigenemia, Cryptococcal meningitis, HIV/AIDS

Brief summary

CRICS financial report for the first budget year of the study

Detailed description

Vietnam Cryptococcal Retention in Care Study (CRICS) federal financial report for the first budget year of the study

Interventions

OTHERVietnam Cryptococcal Retention in Care Study (CRICS)

Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole. Other Names: • Fluconazole

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Aged ≥ 18 years * Confirmed HIV infection using National Testing Algorithm * CD4 ≤100 cells/μL * Able to provide written informed consent

Exclusion criteria

* History of prior CM * Receipt of systemic antifungal medication for more than 4 consecutive weeks within the past 6 months * Currently taking ART or history of ART for more than 4 weeks within the past year * Known to be currently pregnant or planning to become pregnant during the study period

Design outcomes

Primary

Measure	Time frame
The proportion of patients who have advanced HIV disease (CD4 <100)	12 months
Prevalence of CrAg-positivity among HIV patients with advanced disease	12 months
The proportion of patients who have no new opportunistic infections at 12 months	12 months
Mortality rate among HIV patients with advanced disease	12 months

Secondary

Measure	Time frame
The proportion of patients with advanced HIV disease who retain in HIV care at 6 months and 12 months	Up to 12 months

Countries

Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026